Literature DB >> 7498293

Evidence for alterations in presynaptic serotonergic function during withdrawal from chronic cocaine in rats.

M H Baumann1, K M Becketts, R B Rothman.   

Abstract

The effects of repeated cocaine administration on serotonin (5-hydroxytryptamine, 5-HT) function were investigated by comparing the corticosterone response to 5-HT receptor agonists in cocaine-treated and vehicle-treated rats. Male rats were fitted with indwelling jugular catheters and received cocaine (15 mg/kg i.p., b.i.d.) or saline for 7 days. Rats were challenged with either saline, the 5-HT releaser fenfluramine (1.2 mg/kg i.v.), the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT; 50 micrograms/kg i.v.), or the 5-HT2A/2C receptor agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI; 100 micrograms/kg i.v.) 42 h and 8 days after the final chronic treatment. Repeated blood samples were withdrawn immediately before and at 15, 30 and 60 min after acute challenge injections. All 5-HT receptor agonists increased plasma corticosterone, but the fenfluramine-induced rise in corticosterone was significantly attenuated in cocaine-treated rats withdrawn for 42 h. This blunted response to fenfluramine exhibited only partial recovery when examined at 8 days postchronic treatment. Corticosterone responses to 8-OH-DPAT and DOI were not affected by cocaine exposure. Our data suggest that chronic cocaine produces deficits in presynaptic 5-HT function, and alterations in 5-HT neurotransmission may underlie the dysphoria experienced by abstinent cocaine users. Neuroendocrine challenge tests should be performed in human addicts to evaluate potential 5-HT dysfunction associated with cocaine abuse.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7498293     DOI: 10.1016/0014-2999(95)00280-x

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  9 in total

1.  Pharmacological screen for activities of 12-hydroxyibogamine: a primary metabolite of the indole alkaloid ibogaine.

Authors:  J K Staley; Q Ouyang; J Pablo; W L Hearn; D D Flynn; R B Rothman; K C Rice; D C Mash
Journal:  Psychopharmacology (Berl)       Date:  1996-09       Impact factor: 4.530

2.  Abstinence-related changes in sleep during treatment for cocaine dependence.

Authors:  G A Angarita; S V Canavan; E Forselius; A Bessette; B Pittman; P T Morgan
Journal:  Drug Alcohol Depend       Date:  2013-11-17       Impact factor: 4.492

3.  Prolonged deficits in presynaptic serotonin function following withdrawal from chronic cocaine exposure as revealed by 5-HTP-induced head-twitch response in mice.

Authors:  N A Darmani; J Shaddy; E L Elder
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

4.  Voltammetric characterization of the effect of monoamine uptake inhibitors and releasers on dopamine and serotonin uptake in mouse caudate-putamen and substantia nigra slices.

Authors:  Carrie E John; Sara R Jones
Journal:  Neuropharmacology       Date:  2007-03-16       Impact factor: 5.250

Review 5.  Dual dopamine/serotonin releasers: potential treatment agents for stimulant addiction.

Authors:  Richard B Rothman; Bruce E Blough; Michael H Baumann
Journal:  Exp Clin Psychopharmacol       Date:  2008-12       Impact factor: 3.157

6.  Quantification of [1-(5-fluoropentyl)-1H-indol-3-yl](naphthalene-1-yl)methanone (AM-2201) and 13 metabolites in human and rat plasma by liquid chromatography-tandem mass spectrometry.

Authors:  Jeremy Carlier; Karl B Scheidweiler; Ariane Wohlfarth; Bonita D Salmeron; Michael H Baumann; Marilyn A Huestis
Journal:  J Chromatogr A       Date:  2016-05-06       Impact factor: 4.759

7.  Functional consequences of central serotonin depletion produced by repeated fenfluramine administration in rats.

Authors:  M H Baumann; M A Ayestas; R B Rothman
Journal:  J Neurosci       Date:  1998-11-01       Impact factor: 6.167

Review 8.  Animal models and treatments for addiction and depression co-morbidity.

Authors:  Neil E Paterson; Athina Markou
Journal:  Neurotox Res       Date:  2007-01       Impact factor: 3.911

Review 9.  Prenatal drug exposure and neurodevelopmental programming of glucocorticoid signalling.

Authors:  Alexis L Franks; Kimberly J Berry; Donald B DeFranco
Journal:  J Neuroendocrinol       Date:  2019-10-02       Impact factor: 3.870

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.